Patients scramble as cheaper obesity drug alternatives disappear
- Cheaper alternatives to weight-loss drugs like Wegovy and Zepbound are becoming unavailable, leading some patients to seek compounded versions at pharmacies and telehealth companies.
- The FDA has announced that restrictions on compounded versions of tirzepatide and semaglutide will take effect on April 22 and May 22, respectively, impacting many Americans.
- A federal judge denied the request to challenge the FDA's restrictions, stating that compounded drugs lack FDA approval for safety and effectiveness.
- Patients across the U.S. Express concern about losing access to affordable medication, with one stating, 'If I don’t have this medicine available to me, I will 100% gain weight.
9 Articles
9 Articles
Patients scramble as cheaper obesity drug alternatives disappear
When Christina and Jackson Agar used to get a pizza, they’d polish it off the same night. Things are different now that they’re both taking an obesity drug.“We recently ordered a pizza and we ate some of it the first night and then the next day we had maybe a little bit more,” says Christina. “And then we ended up throwing the pizza away because it had gone past the days that you could eat it. And it was so strange because we have never done tha…
Coverage Details
Bias Distribution
- 57% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage